Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 2/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11562750 | 0.98 | CA1 (0.61) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL4661398 | 0.93 | KIF11 (0.68) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL12054668 | 0.89 | KEAP1 (0.75) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL27825435 | 0.88 | HPGD (0.85) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL3112491 | 0.88 | PGR (0.73) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL3099756 | 0.88 | HPGD (0.53) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL31041151 | 0.82 | KIF11 (0.79) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL10892954 | 0.82 | CA1 (0.67) | CA1CA2HPGDALDH1A1KDM4E | |
| P-Cresol SCHEMBL11694488 | 0.82 | CA1 (0.50) | CA1CA2KEAP1HPGDALDH1A1 | |
| SCHEMBL3381347 | 0.80 | ENPP2 (0.54) | CA1CA2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113200891-B | Preparation method of cis-N-styryl amide derivative | 华侨大学 | 2022-09-30 | — | — | CN | claimed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230384496-A1 | OPTICAL MEMBER FOR USE IN DISPLAY DEVICE AND DISPLAY DEVICE INCLUDING DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230372268-A1 | METHODS OF INTRAVENOUSLY ADMINISTERING SOTALOL | AltaThera Pharmaceuticals LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11789307-B2 | Colorant filter, backlight unit, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2023-10-17 | — | — | US | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023159307-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2023-08-31 | — | — | WO | disclosed |
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
| EP-0495594-B1 | Sulphonamide derivatives | ZENECA LTD (GB) | 1996-03-20 | — | — | EP | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
| EP-0495594-A1 | Sulphonamide derivatives | ZENECA LIMITED (GB) | 1992-07-22 | — | — | EP | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | CA1 3580/4885CA2 2618/4885KEAP1 1226/4885 |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | CA1 2508/4885CA2 1670/4885KEAP1 1048/4885 |
| US-20010051730-A1 | Beta-alanine derivative and a process for the preparation thereof | F13B, FGB, TGFB1 | CA1 1175/4885CA2 1729/4885KEAP1 4038/4885 |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | MGAM, LCT, GANAB | CA1 4034/4885CA2 2186/4885KEAP1 593/4885 |
| US-20230372268-A1 | METHODS OF INTRAVENOUSLY ADMINISTERING SOTALOL | TNNT2, CACNA1H, ATP2A1 | CA1 4047/4885CA2 1436/4885KEAP1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.